BPC-157: Separating the Evidence from the Hype
BPC-157 has a large animal-research base and almost no human trial data. A 2025 systematic review found just one human study among 36. Both things are true.
Search “BPC-157” and you’ll find confident claims about healing tendons, guts, and just about everything else. Search the clinical literature and you’ll find something very different: a large body of animal research and an almost empty shelf of human trials.
What the preclinical data shows
BPC-157 is a synthetic peptide derived from a protein found in gastric juice. In rodent models, it has been studied for:
- Tendon, ligament, and muscle healing
- Gut mucosal protection
- Angiogenesis (new blood-vessel formation)
These preclinical signals are why the molecule attracts research interest. But preclinical is the operative word.
Why that isn’t enough
A 2025 systematic review in HSS Journal (Hospital for Special Surgery) set out to map the BPC-157 evidence for orthopaedic sports medicine. Of 544 articles screened, 36 met inclusion criteria — and 35 of those were preclinical animal studies. Exactly one was a human clinical study.
The reviewers found no clinical safety data in humans, and the lone clinical study was a low-level (level IV/V) retrospective report — not a controlled trial.
Animal results translate to humans inconsistently; the history of medicine is full of compounds that healed rats and did nothing for people. For BPC-157 specifically, there are still no published, peer-reviewed, placebo-controlled human trials establishing efficacy or long-term safety. A randomized Phase 2 study in acute hamstring strain (ClinicalTrials.gov NCT07437547) is among the first attempts to generate real human data.
Confidence level
| Claim | Evidence |
|---|---|
| Effects in rodent models | Reproduced across labs |
| Effects in humans | Effectively absent |
| Long-term human safety | Unknown |
It’s also worth noting the regulatory reality: BPC-157 is not FDA approved for any indication and is prohibited in professional sport under WADA rules.
The takeaway
BPC-157 is a legitimate research target, not a proven therapy. The animal data is genuinely interesting; the human data is, for now, almost nonexistent. That’s not a claim it doesn’t work — it’s a claim that we don’t know, and anyone selling certainty about its human effects is ahead of the evidence. We’ll update this page as controlled human trials report.